Andreas Argyrides
Stock Analyst at Wedbush
(4.26)
# 472
Out of 4,734 analysts
100
Total ratings
47.06%
Success rate
18.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $11.41 | +31.46% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $131.06 | +38.10% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $10.77 | +224.98% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $3.43 | +658.02% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $1.26 | +455.56% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $1.41 | +1,105.67% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $13.62 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $45.82 | +126.98% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.92 | +442.24% | 1 | Jun 25, 2024 | |
| GOSS Gossamer Bio | Initiates: Outperform | $9 | $0.92 | +876.14% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $13.48 | +40.95% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $3.21 | +180.37% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.64 | +28.09% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.57 | +177.41% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $116.79 | +91.80% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $22.84 | +149.56% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.79 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.95 | +636.84% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $6.04 | +65.56% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $1.13 | +784.96% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $62.53 | +11.95% | 6 | Aug 1, 2023 |
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $11.41
Upside: +31.46%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $131.06
Upside: +38.10%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $10.77
Upside: +224.98%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $3.43
Upside: +658.02%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $1.26
Upside: +455.56%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $1.41
Upside: +1,105.67%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $13.62
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $45.82
Upside: +126.98%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.92
Upside: +442.24%
Gossamer Bio
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $0.92
Upside: +876.14%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $13.48
Upside: +40.95%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $3.21
Upside: +180.37%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.64
Upside: +28.09%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.57
Upside: +177.41%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $116.79
Upside: +91.80%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $22.84
Upside: +149.56%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.79
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.95
Upside: +636.84%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $6.04
Upside: +65.56%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $1.13
Upside: +784.96%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $62.53
Upside: +11.95%